Literature DB >> 772759

Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies.

H W Seyberth, B J Sweetman, J C Frolich, J A Oates.   

Abstract

Measurement of 7alpha-hydroxy-5,11-diketotetranoprostane-1,16-dioic acid, (PGE-M), the major urinary metabolite of prostaglandin E1 and E2 in man provides a useful indicator to monitor prostaglandin biosynthesis. For quantitative analysis of this prostaglandin metabolite and the stable-isotope dilution techniqe of selected ion monitoring (SIM) is employed using gas-liquid chromatography-mass spectrometry. The preparation of the bis(D3-methyloxime), bis-methyl ester of PGE-M containing a tritium tracer in position 2 which was used as internal standard for the SIM method is described. The synthesis of this internal standard includes the biosynthetic conversion of 11-hydroxy-9,15-diketoprostanoic acid to PGE-M by the rabbit. The intra-assay coefficient of variation of this SIM method ranged between 4.0 to 6.7 percent. The recovery of authentic, underivatized PGE-M added to urine was 93 +/- 3% (mean +/- SEM, n=17). The levels of PGE-M excreted in urine were higher (p less than 0.001) in males than in females (15.2 +/- 1.9 mug/24 hours (n=24) and 3.3 +/- 0.3 mug/24 hours (n=17), respectively. These levels were in close agreement with values published previously. No significant difference in excretion of PGE-M between the sexes was observed in the pre-pubertal age-grou (male: 2.9 +/- 0.8 mug/24 hours, n=5; female: 3.1 +/- 0.9 mug/24 hours, n=5) or in the age-group of 45-80 years (male: 9.3 +/- 1.1 mug/24 hours, n=21; female: 7.3 +/- 0.9 mug/24 hours, n=12). The amount of PGE-M excreted decreased significantly after administration of indomethacin or acetyl salicylic acid in therapeutic doses. The concomitant reduction of the urinary excretion of PGE-M (68 to 85% decrease) and prostaglandin E (73 to 100% decrease) after indomethacin treatment in each case (n=8) is evidence that a diminished urinary PGE-M output reflects a decrease in prostaglandin E biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 772759     DOI: 10.1016/0090-6980(76)90160-x

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  23 in total

1.  Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers.

Authors:  Neil D Gross; Jay O Boyle; Jason D Morrow; Myles K Williams; Chaya S Moskowitz; Kotha Subbaramaiah; Andrew J Dannenberg; Anna J Duffield-Lillico
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Synthesis of tetranor-PGE1: a urinary metabolite of prostaglandins E1 and E2.

Authors:  Jennifer R Kimbrough; Somnath Jana; Kwangho Kim; Alexander Allweil; John A Oates; Ginger L Milne; Gary A Sulikowski
Journal:  Tetrahedron Lett       Date:  2020-04-10       Impact factor: 2.415

Review 3.  Prostaglandin-mediated hypercalcemia: a paraneoplastic syndrome.

Authors:  H W Seyberth
Journal:  Klin Wochenschr       Date:  1978-04-15

4.  Fruit and vegetable intake and urinary levels of prostaglandin E₂ metabolite in postmenopausal women.

Authors:  Sangmi Kim; Joseph Rimando; Dale P Sandler
Journal:  Nutr Cancer       Date:  2015-03-26       Impact factor: 2.900

5.  Mass spectrometric determination of urinary prostaglandins in preterm infants. The basis for an effective and safe therapeutic regimen for the pharmacological closure.

Authors:  H W Seyberth; H Müller; T Erlenmaier; R Mrongovius
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

Review 6.  [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase].

Authors:  D O Stichtenoth; H Zeidler; J C Frölich
Journal:  Med Klin (Munich)       Date:  1998-07-15

7.  Cardiovascular Consequences of Prostanoid I Receptor Deletion in Microsomal Prostaglandin E Synthase-1-Deficient Hyperlipidemic Mice.

Authors:  Soon Yew Tang; James Monslow; Gregory R Grant; Leslie Todd; Sven-Christian Pawelzik; Lihong Chen; John Lawson; Ellen Puré; Garret A FitzGerald
Journal:  Circulation       Date:  2016-07-26       Impact factor: 29.690

8.  Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.

Authors:  Arash Mohebati; Ginger L Milne; Xi Kathy Zhou; Anna J Duffield-Lillico; Jay O Boyle; Allison Knutson; Brian P Bosworth; Philip J Kingsley; Lawrence J Marnett; Powel H Brown; Esther G Akpa; Eva Szabo; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2013-05-16

Review 9.  Targeting the eicosanoid pathway in non-small-cell lung cancer.

Authors:  Leora Horn; Michael Backlund; David H Johnson
Journal:  Expert Opin Ther Targets       Date:  2009-05-02       Impact factor: 6.902

10.  Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.

Authors:  Vikram D Kekatpure; Jay O Boyle; Xi Kathy Zhou; Anna J Duffield-Lillico; Neil D Gross; Nancy Y Lee; Kotha Subbaramaiah; Jason D Morrow; Ginger Milne; Scott M Lippman; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2009-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.